Jacobs Levy Equity Management’s Neurocrine Biosciences NBIX Stock Holding History

Jacobs Levy Equity Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$122M	Buy	726,112 +205,843	+40%	+$30.5M	0.44%	56
2026 Q1	$68.5M	Buy	520,269 +485,343	+1,390%	+$64.4M	0.29%	91
2025 Q4	$4.95M	Sell	34,926 -594	-2%	-$86.1K	0.02%	412
2025 Q3	$4.99M	Sell	35,520 -18,480	-34%	-$2.5M	0.02%	425
2025 Q2	$6.79M	Sell	54,000 -34,915	-39%	-$4M	0.03%	373
2025 Q1	$9.83M	Buy	88,915 +21,726	+32%	+$2.75M	0.04%	340
2024 Q4	$9.17M	Sell	67,189 -456,979	-87%	-$56.5M	0.03%	320
2024 Q3	$60.4M	Sell	524,168 -196,919	-27%	-$27M	0.23%	106
2024 Q2	$99.3M	Buy	721,087 +8,289	+1%	+$1.14M	0.41%	58
2024 Q1	$98.3M	Sell	712,798 -40,067	-5%	-$5.47M	0.44%	53
2023 Q4	$99.2M	Buy	752,865 +60,491	+9%	+$6.96M	0.5%	46
2023 Q3	$77.9M	Buy	692,374 +256,920	+59%	+$27.1M	0.46%	54
2023 Q2	$41.1M	Buy	435,454 +4,118	+1%	+$402K	0.24%	108
2023 Q1	$43.7M	Buy	431,336 +367,229	+573%	+$38.2M	0.27%	94
2022 Q4	$7.66M	Buy	64,107 +50,540	+373%	+$5.92M	0.05%	320
2022 Q3	$1.44M	Buy	+13,567	New	+$1.38M	0.01%	629
2021 Q1	–	Sell	-6,308	Closed	-$605K	–	1086
2020 Q4	$605K	Sell	6,308 -25,173	-80%	-$2.43M	0.01%	823
2020 Q3	$3.03M	Buy	31,481 +3,947	+14%	+$457K	0.03%	441
2020 Q2	$3.36M	Sell	27,534 -122,910	-82%	-$13.6M	0.04%	426
2020 Q1	$13M	Sell	150,444 -11,388	-7%	-$1.11M	0.17%	148
2019 Q4	$17.4M	Buy	161,832 +47,903	+42%	+$5.02M	0.17%	148
2019 Q3	$10.3M	Sell	113,929 -20,450	-15%	-$1.91M	0.13%	206
2019 Q2	$11.3M	Buy	134,379 +50,210	+60%	+$4.12M	0.16%	172
2019 Q1	$7.42M	Buy	+84,169	New	+$7.04M	0.11%	258

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jacobs Levy Equity Management's NBIX Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its Neurocrine Biosciences (NBIX) stake by 40% in Q2 2026, buying an estimated $30.5M and bringing the position to 726,112 shares worth $122M. The position accounts for 0.44% of the portfolio, ranked #56.

Jacobs Levy Equity Management first reported a position in NBIX in Q1 2019 and has held it in 24 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Jacobs Levy Equity Management held 726,112 shares of Neurocrine Biosciences worth $122M as of Q2 2026.
Jacobs Levy Equity Management bought 205,843 Neurocrine Biosciences shares in Q2 2026, an estimated $30.5M.
Neurocrine Biosciences made up 0.44% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #56 holding.
Jacobs Levy Equity Management first reported a position in Neurocrine Biosciences in Q1 2019 and has held it in 24 quarters since.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.